---
title: "BioNTech’s rally on Moderna trial win likely to fade, Leerink says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296380155.md"
description: "Leerink Partners analyst Daina Graybosch predicts BioNTech's recent 21% rally will fade, despite Moderna and Merck's Phase 3 trial success for a melanoma therapy. She argues investors will absorb poor read-through for BioNTech, whose iNEST program has been negatively impacted by prior negative data."
datetime: "2026-08-19T16:16:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296380155.md)
  - [en](https://longbridge.com/en/news/296380155.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296380155.md)
generator: "portal-rs"
---

# BioNTech’s rally on Moderna trial win likely to fade, Leerink says


### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [Moderna Chief Legal Officer Shannon Thyme Klinger disposes of USD 485,271.45 in common shares](https://longbridge.com/en/news/297958452.md)
- [Moderna Raises $3.0 Billion via 2032 Zero-Coupon Converts; Adds Capped Calls to Limit Dilution](https://longbridge.com/en/news/297697426.md)
- [Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It](https://longbridge.com/en/news/298134130.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**